Anoro Ellipta now available in retail pharmacies

LONDON — GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single inhaler, is now available in retail pharmacies in the United States.



Anoro Ellipta is used for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. It is not indicated for the relief of acute bronchospasm or the treatment of asthma. The FDA-approved strength is umeclidinium/vilanterol 62.5/25-mcg.



“We understand that COPD is a progressive disease affecting an estimated 27 million people in the U.S. alone,” said Jorge Bartolome, SVP of the GSK respiratory business unit in the United States. “Anoro Ellipta is an important treatment option for appropriate patients with COPD, and we are proud to make it available in the U.S.”    



The FDA approved Anoro Ellipta on Dec. 18, 2013.